Establishment Labs (NASDAQ:ESTA) Trading 7.1% Higher - Here's Why

Key Points

• Establishment Labs Holdings Inc. (NASDAQ:ESTA) saw a significant increase in its stock price, trading up 7.1% to $39.45 during recent trading, despite an overall decline in trading volume.
• Analysts have varying opinions on the stock, with Canaccord Genuity setting a target at $60.00 and Citigroup raising their target to $47.00, indicating a “Moderate Buy” average rating.
• The company reported a quarterly EPS of ($0.57), slightly missing estimates, but with a revenue increase of 16.1% year-over-year, suggesting growth potential amidst negative net margins.

Establishment Labs Holdings Inc. (NASDAQ:ESTA - Get Free Report)'s share price traded up 7.1% during mid-day trading on Tuesday . The stock traded as high as $39.42 and last traded at $39.45. 61,627 shares traded hands during trading, a decline of 88% from the average session volume of 503,004 shares. The stock had previously closed at $36.84.

Analysts Set New Price Targets

Several research firms have recently weighed in on ESTA. Canaccord Genuity Group began coverage on shares of Establishment Labs in a research report on Wednesday, August 20th. They issued a "buy" rating and a $60.00 target price for the company. Citigroup boosted their target price on shares of Establishment Labs from $38.00 to $47.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 9th. Needham & Company LLC reissued a "buy" rating and issued a $48.00 target price on shares of Establishment Labs in a research report on Friday, June 13th. Wall Street Zen downgraded shares of Establishment Labs from a "hold" rating to a "sell" rating in a research report on Saturday, August 16th. Finally, Mizuho boosted their target price on shares of Establishment Labs from $58.00 to $70.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 16th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, Establishment Labs presently has an average rating of "Moderate Buy" and a consensus price target of $56.50.

Establishment Labs Stock Up 6.3%

The firm's 50 day simple moving average is $40.67 and its 200 day simple moving average is $37.94. The company has a market cap of $1.13 billion, a price-to-earnings ratio of -12.83 and a beta of 0.85. The company has a quick ratio of 1.67, a current ratio of 2.84 and a debt-to-equity ratio of 9.71.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.03). The firm had revenue of $51.30 million during the quarter, compared to analyst estimates of $50.80 million. Establishment Labs had a negative net margin of 49.89% and a negative return on equity of 224.34%. Establishment Labs's revenue for the quarter was up 16.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.62) EPS. Establishment Labs has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that Establishment Labs Holdings Inc. will post -2.41 EPS for the current fiscal year.

Institutional Trading of Establishment Labs

Institutional investors have recently made changes to their positions in the stock. Elevation Point Wealth Partners LLC acquired a new stake in Establishment Labs during the first quarter valued at approximately $207,000. New York State Common Retirement Fund acquired a new stake in Establishment Labs during the first quarter valued at approximately $894,000. Mudita Advisors LLP lifted its stake in Establishment Labs by 15.6% during the first quarter. Mudita Advisors LLP now owns 479,359 shares of the company's stock valued at $19,560,000 after purchasing an additional 64,859 shares during the last quarter. Northern Trust Corp lifted its stake in Establishment Labs by 53.9% during the fourth quarter. Northern Trust Corp now owns 28,165 shares of the company's stock valued at $1,298,000 after purchasing an additional 9,865 shares during the last quarter. Finally, Swiss National Bank lifted its stake in Establishment Labs by 1.3% during the first quarter. Swiss National Bank now owns 39,000 shares of the company's stock valued at $1,591,000 after purchasing an additional 500 shares during the last quarter. 72.91% of the stock is owned by institutional investors and hedge funds.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.